Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation. Axsome ...

Axsome’s portfolio includes FDA-approved treatments for major depressive disorder, narcolepsy, obstructive sleep apnea, and migraine. The company, currently valued at $6.12 billion, is also ...

Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...

Axsome Therapeutics is a biopharmaceutical company ... associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome anticipates submitting the planned sNDA ... associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range ...

Axsome's drug was given a breakthrough designation ... Next up is AXS-07 (meloxicam/rizatriptan) for acute treatment of migraine, which was turned down by the FDA at its first attempt in May ...

Axsome’s portfolio includes FDA-approved treatments for major depressive disorder, narcolepsy, obstructive sleep apnea, and migraine. The company, currently valued at $6.12 billion, is also advancing ...